Intensity Therapeutics (INTS) Interest & Investment Income (2022 - 2026)
Intensity Therapeutics' (INTS) quarterly Interest & Investment Income came in at $94000.0 in Q1 2026, up 526.67% YoY from $15000.0 in Q1 2025, and up 6.82% on a QoQ basis from $88000.0 in Q4 2025.
Intensity Therapeutics (INTS) Interest & Investment Income (2022 - 2026) Analysis & Trends
Intensity Therapeutics (INTS) has 5 years of Interest & Investment Income data on file, last reported at $94000.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 526.67% year-over-year to $94000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $258000.0 (up 36.51% YoY) and the FY2025 annual result came in at $180000.0, down 42.68% from the prior year.
- Interest & Investment Income advanced to $94000.0 in Q1 2026, from $88000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $176000.0 in Q4 2023 to a low of $156.0 in Q4 2022.
- A 5-year average of $65168.4 and a median of $53500.0 in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2023 — Interest & Investment Income surged 112720.51% — and 2025, when it plunged 89.29%.
- Tracing INTS's Interest & Investment Income over 5 years: stood at $156.0 in 2022, then surged by 112720.51% to $176000.0 in 2023, then tumbled by 84.09% to $28000.0 in 2024, then soared by 214.29% to $88000.0 in 2025, then grew by 6.82% to $94000.0 in 2026.
- The last three Interest & Investment Income figures came in at $94000.0 (Q1 2026), $88000.0 (Q4 2025), and $59000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Intensity Therapeutics | 12.99 Mn | 12.99 Mn | - | 77,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 77,000.00 |
| Mar 31, 2026 | 94,000.00 |
| Dec 31, 2025 | 88,000.00 |
| Sep 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 17,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Dec 31, 2024 | 28,000.00 |
| Sep 30, 2024 | 48,000.00 |
| Jun 30, 2024 | 98,000.00 |
| Mar 31, 2024 | 140,000.00 |
| Dec 31, 2023 | 176,000.00 |
| Sep 30, 2023 | 148,000.00 |
| Dec 31, 2022 | 156.00 |
| Sep 30, 2022 | 988.00 |
| Jun 30, 2022 | 213.00 |